EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

Mehmet Altan iD, Yan Wang, Juhee Song, James Welsh, Chad Tang iD, Nandita Guha-Thakurta, George R Blumenschein, Brett W Carter, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, Mary Frances McAleer und 15 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-006871 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Mehmet Altan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Bristol-Myers Squibb, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery. There are no prospective data on the safety of stereotactic radiosurgery (SRS) concurrent with immune checkpoint inhibitor therapy for BM. This is the safety cohort of the phase I/II investigator-initiated trial of SRS with nivolumab and ipilimumab for patients with BM from NSCLC. Patients and methods This single-institution study included patients with NSCLC with active BM amenable to SRS. Brain SRS and systemic therapy with nivolumab and ipilimumab were delivered concurrently (within 7 days). The endpoints were safety and 4-month intracranial progression-free survival (PFS).

Results

Thirteen patients were enrolled in the safety cohort, 10 of whom were evaluable for dose-limiting toxicities (DLTs). Median follow-up was 23 months (range 9.7–24.3 months). The median interval between systemic therapy and radiation therapy was 3 days. Only one patient had a DLT; hence, predefined stopping criteria were not met. In addition to the patient with DLT, three patients had treatment-related grade ≥3 adverse events, including elevated liver function tests, fatigue, nausea, adrenal insufficiency, and myocarditis. One patient had a confirmed influenza infection 7 months after initiation of protocol treatment (outside the DLT assessment window), leading to pneumonia and subsequent death from hemophagocytic lymphohistiocytosis. The estimated 4-month intracranial PFS rate was 70.7%.

Conclusion

Concurrent brain SRS with nivolumab/ipilimumab was safe for patients with active NSCLC BM. Preliminary analyses of treatment efficacy were encouraging for intracranial treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryHumansIpilimumabNivolumabCombined Modality Therapy

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsNon-Small Cell Lung CancerRadiotherapy

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Mehmet Altan, Chad Tang, Marcelo V Negrao

Förderung

  • NCI NIH HHS
  • Bristol-Myers Squibb
  • NIH/NCI

Zitieren

APA

Altan, M., Wang, Y., Song, J., Welsh, J., Tang, C., Guha-Thakurta, N., Blumenschein, G. R., Carter, B. W., Wefel, J. S., Ghia, A. J., Yeboa, D. N., McAleer, M. F., Chung, C., Woodhouse, K. D., McGovern, S. L., Wang, C., Kim, B. Y. S., Weinberg, J. S., Briere, T. M., …, & Li, J. (2023). Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006871

Vancouver

Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, et al. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006871

BibTeX
@article{Altan2023,
  author = {Altan, Mehmet and Wang, Yan and Song, Juhee and Welsh, James and Tang, Chad and Guha-Thakurta, Nandita and Blumenschein, George R and Carter, Brett W and Wefel, Jeffrey S and Ghia, Amol J and Yeboa, Debra N and McAleer, Mary Frances and Chung, Caroline and Woodhouse, Kristina D and McGovern, Susan L and Wang, Chenyang and Kim, Betty Y S and Weinberg, Jeffrey S and Briere, Tina M and Elamin, Yasir Y and Le, Xiuning and Cascone, Tina and Negrao, Marcelo V and Skoulidis, Ferdinandos and Ferrarotto, Renata and Heymach, John V and Li, Jing},
  title = {Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-006871}
}
Kostenlos starten →